Prior Authorization Required and Protocol Details

Prior authorization is required for device‑based TMS therapies and documentation must demonstrate prior antidepressant treatment and treatment‑resistant status. Requests should include the indication, targeted brain region/modality (rTMS, dTMS, navigated TMS, tDCS/CES), proposed stimulation parameters (frequency, intensity relative to motor threshold, pulses/session, number of sessions, tapering plan), and the supervising psychiatrist’s order and oversight plan.

• Device‑based TMS (rTMS/dTMS/navigated TMS) — anticipate prior authorization
• Submission must specify modality, target region, stimulation frequency, intensity (eg, % of motor threshold), total pulses, sessions and tapering
• Psychiatrist order certifying direct supervision and oversight of motor threshold determination

Prior Antidepressant Trials and Evidence of Treatment Resistance

Prior authorization should document prior adequate antidepressant trials in the current depressive episode (typically within the past 5 years) including: two antidepressants from different classes at minimally effective therapeutic doses each for ≥8 weeks, and/or an adequate augmentation trial (defined below). Evidence of treatment resistance (failure of these trials) must be clear in the record.

• Two antidepressants from ≥2 different classes, each ≥8 weeks at minimally effective dose
• OR an augmentation strategy (see Appendix) used for ≥8 weeks counts as an adequate trial
• Document dates, doses, tolerability, and source verification when possible (eg, pharmacy records)

Consider Prior Treatment Resistance and Alternatives

Prior authorization reviewers should consider prior treatment resistance and prior trials when evaluating requests. When TMS is proposed after pharmacotherapy failure, document prior medication optimization, trials of augmentation strategies, intolerance or contraindications to alternatives (including ECT when relevant), and the rationale for choosing TMS.

• Confirm whether ECT was considered or contraindicated — ECT may be preferred for some treatment‑resistant cases
• Document prior medication strategies tried and whether augmentation was attempted
• Describe why device TMS is being selected over other options

PA Recommended Given Limited Routine‑Use Evidence

Because high‑quality evidence is limited or inconsistent for many non‑depression indications and for routine long‑term benefit, prior authorization is recommended for TMS/tDCS/CES uses outside clear FDA‑labeled indications. Reviewers should require submitted evidence and rationale for routine or extended use in investigational indications.

• Routine use unsupported in several Cochrane and guideline reviews — require protocol and evidence for routine stroke, chronic pain, and other non‑MDD indications
• PA recommended for investigational or off‑label indications (eg, addiction, TBI, epilepsy)

Prior Authorization for rTMS in SCI‑Associated Neuropathic Pain

For spinal cord injury (SCI)–associated neuropathic pain, evidence is mixed and small RCTs produce inconclusive results. Prior authorization should require documentation of prior conservative therapies, the specific neuropathic pain diagnosis, proposed target (eg, M1), stimulation parameters, and evidence supporting trial use in the patient.

• Document prior conservative therapies attempted and response
• Specify stimulation site (eg, primary motor cortex or DLPFC), frequency, intensity, and number of sessions
• Provide rationale and supporting literature when requesting coverage for SCI‑related neuropathic pain

Potential Prior Authorization for Investigational/Novel Uses

Many indications remain investigational (eg, addiction, some pain syndromes, TBI, epilepsy applications beyond small studies). Payers should consider prior authorization for these novel uses and expect submission of supporting evidence and an a priori protocol describing outcomes and safety monitoring.

• Treat addiction, TBI, and similar uses as experimental — require protocol and evidence submission
• If used clinically, specify concomitant treatments and outcome measures in the PA request

Prior Authorization Likely Required for Device TMS

Device‑based TMS treatments are likely to require prior authorization. The device must be FDA‑cleared for the requested indication and treatment should generally follow manufacturer protocols; deviations (including intensity adjustments) should be justified with evidence.

• Confirm device clearance status for the indication (eg, NeuroStar for MDD; Brainsway for OCD)
• Treatments should follow device labeling and manufacturer parameters unless supported by peer‑reviewed evidence

Protocol Intensity Deviations Affect Efficacy

Protocol intensity deviations can affect efficacy. Adequate stimulation intensity (commonly ~120% of individual motor threshold in trials) is important; lower intensities may reduce clinical response, and higher intensities must be within safety guidance.

• Document planned intensity as % of motor threshold and how threshold will be determined
• If intensity will be reduced for tolerability, provide rationale and expected effect on efficacy

Potential Denial Trigger for Tinnitus rTMS Without Demonstrated Benefit

Tinnitus studies show mixed results; some trials find no benefit versus sham. Requests for tinnitus rTMS should include evidence the proposed protocol has demonstrated benefit for the tinnitus subtype and clear outcome measures; absence of supportive evidence may be a denial trigger.

• Document tinnitus subtype, prior therapies tried, and justification for the selected target and protocol
• Cite randomized evidence showing benefit for the exact stimulation parameters and target region

Routine Use Unsupported in Cochrane and Guideline Reviews

Several Cochrane reviews and technology assessments do not support routine use of rTMS for some conditions (eg, stroke) due to limited or inconsistent evidence. Such findings may support prior authorization and denial decisions when robust RCT evidence is lacking.

• Cochrane reviews found insufficient evidence to support routine rTMS for stroke
• Use review conclusions as rationale for requiring PA and conservative coverage decisions

Evidence Limitations May Affect Coverage

Evidence limitations — small samples, short durations, heterogeneity, and risk of bias — may affect coverage decisions. Reviewers may deny requests when high‑quality comparative evidence (durability, patient‑centered outcomes) is absent for the requested indication or protocol.

• Expect denials or requests for additional evidence for indications with low‑strength or inconsistent trial data
• Large, long‑term RCTs and head‑to‑head comparisons (eg, vs ECT) strengthen the case for coverage

Safety and Efficacy Limitations for Epilepsy Applications

For epilepsy and status epilepticus applications, evidence is very limited, largely retrospective, with short‑lived responses and a small but measurable seizure induction risk. Routine use is not recommended and prior authorization should require detailed risk/benefit justification and safety monitoring plans.

• Seizure induction risk estimated in pooled reports (~2–3%) — document baseline seizure frequency and potential confounders
• For status epilepticus uses, provide case‑level evidence and plan for monitoring and relapse management

No Explicit Universal Authorization Requirements Stated

No single explicit universal authorization checklist is provided in the source documents; however, providers should anticipate PA for many TMS/device‑based interventions and submit comprehensive clinical documentation to support medical necessity.

• There is no exhaustive PA code list in the sources — check payer‑specific PA forms and code lists
• When in doubt, submit a PA with full documentation described in other callouts

Reimbursement Risk Noted in Real‑World Data

Real‑world analyses indicate reimbursement risk for some device indications (eg, dTMS for OCD was often paid out‑of‑pocket in early post‑marketing practice). Providers should confirm coverage and prior authorization policies before treatment.

• dTMS for OCD had limited insurance reimbursement early post‑marketing — verify coverage and PA needs
• Document patient financial counseling when coverage is uncertain

Evidence Insufficiency May Trigger Denial

Evidence insufficiency (small, short trials, heterogeneity, inadequate blinding) may trigger denials for indications where clinical benefit is uncertain. PA reviewers should require robust outcome measures and longer follow‑up in requests for coverage.

• Provide RCT-level evidence showing meaningful clinical outcomes and durability to avoid denials
• When only small/short trials exist, include a plan for outcomes monitoring and retreatment criteria

Evidence Quality Limits Coverage Confidence

Quality limits in the literature (risk of bias, small sample sizes, variable blinding) reduce confidence in efficacy estimates; reviewers should weigh study quality when adjudicating coverage and may deny when evidence quality is low.

• Cite higher‑quality trials and meta‑analyses when available; note limitations of smaller, biased studies
• Document how the requested protocol aligns with higher‑quality evidence

Medication Trial Adequacy Note

Trials of medications not approved in the United States do not count as adequate antidepressant or augmentation trials for the purposes of meeting prior‑treatment requirements.

• Only FDA‑approved antidepressants and augmenting agents (or documented FDA‑approved augmentation strategies) count toward adequacy
• Non‑U.S. drug trials should not be used to meet step‑therapy requirements

References Segment — No Additional Authorization Rules

This section contains references and does not itself specify additional authorization rules. Providers should use the references to support PA requests and to document the evidence base for the requested therapy.

• Include pertinent citations from the References to support clinical rationale
• References document the evidence base but do not replace required clinical documentation

Required Documentation for Prior Authorization

Required documentation for PA should include: psychiatrist‑confirmed diagnosis of severe MDD (or other target diagnosis) using standardized rating scales at baseline and serially; documentation of prior adequate trials (medication and augmentation) with doses and durations; contraindications; and the supervising psychiatrist’s order.

• Baseline and ongoing validated rating scale scores (eg, MADRS, HDRS, BDI) with dates
• Verification of prior antidepressant and augmentation trials (doses, dates, source)
• Statement of contraindications and safety considerations

Document Prior Treatment Resistance

Prior treatment resistance documentation should specify the number, class, dose, and duration of prior antidepressant trials and any augmentation strategies tried or intolerances documented. When available, corroborate with pharmacy records or clinician notes.

• List each antidepressant/augmentation agent, start/stop dates, maximum tolerated dose, and reason for discontinuation or failure
• If trials involved non‑U.S. drugs, note they do not count toward adequacy

Document Prior Treatments and Concurrent Medications

Document prior treatments and concurrent medications. Many trials continued or restarted antidepressant therapy during TMS; PA requests should list current psychotropic medications and any concurrent therapies that will continue during TMS.

• Provide a current medication list with doses and start dates, including antidepressants and augmentation agents
• State whether medications will be held, changed, or continued during the TMS course

Clinical Outcomes and Protocol Documentation

Clinical outcomes and protocol documentation should include the selected outcome measures, planned timing of assessments, response/remission criteria, retreatment criteria, and safety monitoring plans. Outcome measures should be appropriate to the indication (eg, MADRS/HAMD for depression, UPDRS for Parkinson disease, THI for tinnitus).

• Specify primary and secondary outcome measures and the schedule for assessments
• Define response/remission thresholds and criteria for relapse or retreatment

Outcome Measures and Follow‑Up Documentation

Outcome measures and follow‑up documentation: include validated scales and planned follow‑up intervals to assess durability (eg, 3–6 month follow‑up when available). Provide plans for maintenance or tapering sessions and criteria for re‑introduction.

• Baseline and serial validated scale scores with dates (eg, MADRS, HDRS, YBOCS, THI, UPDRS)
• Planned follow‑up timeline and retreatment/maintenance strategy

Safety Documentation Recommended

Safety documentation is recommended. Include seizure risk assessment, contraindications (eg, cranial metal), adverse event monitoring plan, and procedures for seizure management when applicable. For devices producing loud sounds (eg, dTMS), note hearing protection plans.

• Assess and document seizure history and baseline seizure frequency when relevant
• Document plans for monitoring adverse events and emergency procedures during sessions

Clinical Documentation Supporting TMS Use

Clinical documentation supporting TMS use should include the indication, modality, exact target region, treatment parameters, supervising clinician, and expected clinical endpoints. For navigated TMS mapping, include mapping parameters and how mapping results will be used in care.

• State modality (rTMS, dTMS, navigated TMS, tDCS/CES) and targeted brain region(s) with rationale
• For navigated TMS, include mapping coordinates, motor hotspots, and integration with surgical planning if applicable

Use of Y‑BOCS for OCD Outcome Documentation

For OCD, the Yale‑Brown Obsessive Compulsive Scale (Y‑BOCS) is the primary outcome measure used in trials and registries. PA requests for dTMS/OCD should include baseline and planned serial Y‑BOCS assessments and define response criteria (commonly ≥30% reduction).

• Provide baseline Y‑BOCS and planned post‑treatment Y‑BOCS schedule
• Define response (eg, ≥30% reduction) and sustainment criteria

Participant Characterization and Medication Status

Participant characterization and medication status are important: document psychiatric comorbidities, severity, prior response patterns, and concurrent psychotropic medications, since these factors influence outcomes and interpretation of evidence.

• Provide comorbidity list (eg, psychosis, substance use) and how these affect eligibility
• List concurrent psychotropics and whether medication changes are planned during the TMS course

Reference List Only — No Additional Documentation Rules

Reference list only; this segment does not itself impose authorization or documentation rules. Use the references to support clinical rationale and cite when submitting prior authorization requests.

• Include relevant citations from the References in PA submissions to support clinical justification

Step‑Therapy Requirement

Step‑therapy requirement: TMS for major depressive disorder is generally covered only after failed adequate pharmacotherapy — commonly defined as two antidepressants from different classes (or augmentation strategy) during the current episode; verify payer‑specific step‑therapy rules.

• Two antidepressants from different classes each ≥8 weeks at adequate dose OR adequate augmentation strategy
• Confirm whether prior trials occurred in the current depressive episode (typically within past 5 years)

Step‑Therapy: Confirm Prior Medication Strategies Tried

Confirm prior medication strategies tried as part of step‑therapy review. Evaluate whether medications were used at therapeutic doses and durations and whether augmentation (per Appendix definitions) was attempted before TMS.

• Check adherence, dosing adequacy, and documentation for each trial
• Augmentation is defined as two antidepressants with different mechanisms, or antidepressant plus FDA‑approved adjunct (antipsychotic, lithium, or T3)

ECT Precedence in Some Treatment‑Resistant Cases

ECT precedence in some treatment‑resistant cases: clinical guidelines note ECT as the most effective therapy for medication non‑responders. When ECT is clinically appropriate, document whether ECT was considered, attempted, contraindicated, or refused.

• Document ECT consideration, contraindications, or patient refusal when relevant to choosing TMS
• If ECT was deferred, provide rationale (eg, medical contraindications, patient preference)

Require Concurrent Conventional Rehabilitation When Indicated

Require concurrent conventional rehabilitation for some neurologic indications (eg, post‑stroke motor recovery). Evidence often combined rTMS/tDCS with physical or occupational therapy; PA should specify concurrent rehab plans when applicable.

• For stroke or motor rehabilitation, document planned neurorehabilitation modalities and timing relative to stimulation
• Time‑locked stimulation combined with therapy should be described in the protocol

Consider Established Therapies Before Neuromodulation

Consider established therapies first for indications where evidence is preliminary (eg, dementia-related symptoms, fibromyalgia). PA reviewers should expect documentation that guideline‑recommended conservative therapies were attempted prior to device therapy.

• Document trials of exercise, cognitive therapies, standard pharmacologic options, or other guideline‑recommended care
• Explain why TMS/tDCS is being pursued despite existing standard therapies

No Explicit Step‑Therapy Rules Provided in References

No explicit step‑therapy rules are provided in the references segment; payers should apply the policy’s step‑therapy requirements and require documentation described elsewhere in this section.

• If payer uses different step‑therapy rules, follow payer‑specific protocols
• References do not replace documented medication trials and augmentation evidence required for PA

Placement After Inadequate Response to First‑Line Therapy

Placement after inadequate response to first‑line therapy: several authors recommend dTMS/rTMS as an option for patients who have not responded adequately to pharmacologic and psychological interventions. Document the first‑line therapies tried and the rationale for escalation to TMS.

• Explain prior psychotherapy and pharmacotherapy, including durations and outcomes
• Provide objective measures showing inadequate response

Document Prior Conservative Therapies

Document prior conservative therapies for non‑depression indications (eg, peripartum depression, chronic pain). Include prior psychotherapies, medications when appropriate, rehabilitation, and reason for their insufficiency.

• List conservative treatments tried, dates, and responses
• For peripartum depression, document counseling on medication risks/benefits and why TMS is preferred or necessary

Augmentation Therapy Definition

Augmentation therapy is defined as any of: two FDA‑approved antidepressants with different mechanisms used concomitantly; an FDA‑approved antidepressant plus a second‑generation antipsychotic approved for augmentation; antidepressant plus lithium; or antidepressant plus T3. Documentation of adequate augmentation (dose and duration) counts toward meeting prior‑treatment requirements.

• Provide agent names, doses, dates, and objective response measures for augmentation trials
• Only FDA‑approved augmentation strategies count toward adequacy

Step‑Therapy Adequacy

Step‑therapy adequacy: medication trials using drugs not approved in the U.S. do not qualify as adequate trials of antidepressants or augmenting agents. PA requests relying on non‑U.S. medication trials should supply alternative evidence of adequate treatment attempts.

• Verify FDA approval status for agents cited as adequate trials
• If non‑U.S. agents were used, provide documented attempts with FDA‑approved alternatives

No Step‑Therapy Rules in References Segment

No step‑therapy rules appear in the References segment; use the policy’s clinical criteria and Appendix definitions to adjudicate adequacy and step‑requirements for PA.

• Apply the policy’s defined criteria for adequate trials and augmentation rather than relying solely on referenced studies